DOI: 10.53469/jcmp.2025.07(02).04

Research Progress on Glial Cells in Neurodegenerative Diseases

Jiawei Zeng[1,2], Chao Jiang[2,*]

[1]The Second Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China
[2]The Second Affiliated Hospital of Xi'an Medical University, Xi'an 710003, Shaanxi, China
Correspondence Author

Abstract: ***This review discusses glial cells in neurodegenerative diseases as represents their role and scientific advances. Glial cells specifically offer support to neurons in all fields of normal functioning while also participating in processes such as damage and repair under pathological minutiae. The article discusses the above with respect to Alzheimer's, Parkinson's, multiple sclerosis, and other neurodegenerative ailments by combining the latest research findings to discuss potential therapeutic targets and intervention avenues. It emphasizes that understanding glial cell functions and their engages with neurons can be critical as they develop novel treatment approaches for such debilitating conditions.***

Keywords: Glial cells, Neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Multiple sclerosis.

1. Introduction

Basically, neurodegenerative diseases can be described as those diseases involving the gradual degeneration of both neuronal and glial cells, now also considered important due to their wide-ranging effects on cognitive, motor, and emotional functions in these patients. Cells that would be part of this complex are astrocytes, microglia and oligodendrocytes that are increasingly becoming recognized as having a key role in the pathogenesis of these diseases. Recent studies have brought forth the multiple roles they play in maintenance and health of neurons, regulation of inflammation and the next stage of neurorepair. Understanding the glial-associated mechanisms through which the progression of neurodegenerative diseases occurs is crucial to the development of new therapeutic strategies aimed at reducing neuronal loss and replacing the lost functions of the brain [1].

Astrocytes, the most abundant type of glial cell in the CNS, play an important role in neuronal homeostasis. They support neurons metabolically, regulate synaptic transmission, and modulate neuroinflammation. Reactive astrocytes occur during neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease, bringing about protective versus detrimental effects. While reactive astrocytes facilitate blood-brain barrier repair and release neurotrophic factors, reactive astrocytes may have an overactivation leading to neuroinflammation and aggravation of neuronal death [2]. Furthermore, alterations in astrocytic metabolism have been implicated in the pathophysiology of these diseases, underscoring the importance of astrocyte function in neurodegeneration [3].

The binding of microglia, the resident immune cells of the CNS, to neurodegenerative diseases is like a double-edged sword. They are required for the scrutiny of neuronal health and the elimination of cell debris; however, when persistently activated, they lead to neuroinflammation, which then contributes to neuronal death. Microglial activation in neurodegenerative diseases, such as AD and ALS, is associated with the accumulation of neurotoxic and misfolded proteins, like amyloid-β and tau, known as the two hallmark proteins of these diseases [4]. The dysregulation of microglial function, particularly their metabolic activity, has been shown to exacerbate neurodegenerative processes, suggesting that targeting microglial metabolism may offer a novel therapeutic approach [5].

However, recent studies have emphasized the advanced role of oligodendrocytes in neurodegeneration, particularly in myelination and their support of axonal integrity. Oligodendrocyte dysfunction, therefore, has been implicated in a variety of neurodegenerative diseases, such as multiple sclerosis and ALS. Loss of oligodendrocytes leads to demyelination of axons, which, in turn, disrupts neuronal signaling to contribute to the progression of the disease [6]. Understanding the signaling pathways and metabolic changes of oligodendrocytes during neurodegeneration is thus essential for the development of strategies directed at remyelination and restoring neurons to function again [7].

In conclusion, involvement of glial cells in neurodegenerative diseases is diverse in functions, ranging from supportive to various aspects involving neuronal health, regulation of inflammation, and even contribution to the pathology of the disease. As research continually illuminates the complexities of the glial cell functions, there arises compelling evidence that targeting these cells could translate into new advantages for therapeutic intervention in neurodegenerative diseases. Future studies should focus on elaborating precise mechanisms through which glial cells are engaged in neurodegeneration and on finding ways to modulate their activity for neuroprotective purposes [8].

2. Glial Cells

2.1 Basic Functions of Glial Cells

Glial cells, called support cells from the neuroscience perspective, are slightly more complicated than that, since they serve multiple roles in support of the neurons. In other words, they maintain homeostasis, provide metabolic support, facilitate communication in the brain, etc. Glial cells are divided into a few types; astrocytes, microglia, and oligodendrocytes are the broad forms. They exhibit certain distinctive properties and functions. While astrocytes are

known to contribute to maintaining the blood-brain barrier and regulation of neurotransmitter levels, the microglia assume the role of the primary defense in the CNS as immune responders to insult and disease. Oligodendrogliocytes arise from pre-oligodendrocytes, which are responsible for the myelinating of axons, essential for fast signal transmission. Emerging research has demonstrated that glial cells exhibit plasticity that allows them to undergo considerable structural and functional changes when exposed to environmental stimuli common during neuroinflammation and metabolic transition in various neurodegenerative disorders [1,4]. This adaptability underscores the importance of glial cells in both healthy brain function and the pathophysiology of neurological disorders.

2.1.1 Types and Characteristics of Glial Cells

Different classification systems exist for glial cells, establishing various glial cell types, each of which has distinct properties and functions. Among them are the most important groups: astrocytes, microglia, oligodendrocytes, and ependymal cells. Astrocytes, the star-shaped cells, provide structural support, regulate blood flow, and maintain the extracellular environment for neurons. They are also involved in neurotransmitter uptake or release, thus performing an essential role in synaptic function. Microglia are the resident immune cells of the CNS; they sense the environment for any signs of injury or infection and regulate the function of neurons through the immune system. When there is damage, microglia can quickly respond by becoming activated and proliferating and phagocytosing any cellular debris. Oligodendrocytes are specialized glial cells that insulate axons by myelination, thus allowing for rapid electric conduction. Recently, the identification of the functional role of ependymal cells in the production of cerebrospinal fluid and maintenance of the microenvironment in the brain has further extended the role of glial cells [5] [6]. Glial cell types are associated with a unique function, demonstrating how vital they are for maintaining normal health and functionality in the CNS.

2.1.2 The Role of Glial Cells in Neuroprotection

The actions of glia are far-reaching in neuroprotection. Glial cells provide sustenance necessary for the maintenance of neurons and their survival in a state of physiological or pathological condition. They achieve this in a variety of ways, including neurotrophic factor release, inflammatory responses control, and maintenance of the blood-brain barrier. For instance, astrocytes express and release neurotrophic factors, like BDNF, involved in neuronal survival and in synaptic plasticity. Glial cells can also modulate various aspects of inflammatory responses in neurodegenerative processes by diminishing damage incurred through neuroinflammation [2,3]. Under conditions such as Alzheimer's disease, glial cells have been shown to aid in the clearance of amyloid-beta plaques, thus lessening their neurotoxic effects. Dysregulation in the function of glial cells, however, may lead to amplified neuroinflammation and neuronal death, emphasizing the dual role of glial cells, as protectors and agents for neurodegeneration [9,10]. Understanding these mechanisms is crucial for developing targeted therapies aimed at enhancing glial cell function to protect against neurodegenerative diseases.

2.1.3 Interactions Between Glial Cells and Neurons

Interactions between glial cells and neurons are basic for the proper functioning of the nervous system. These interactions are bidirectional and are governed by complex signaling pathways that allow for communication and metabolic support. Astrocytes secrete gliotransmitters that may modulate neuronal excitability and synaptic transmission; in turn, neurons communicate with glial cells through neurotransmitter signaling [11,12]. In addition, neuronal activity would promote the proliferation and differentiation of oligodendrocyte precursor cells (OPCs) into myelinating oligodendrocytes. Such dynamic interplay is critical in the maintenance of neural circuit integrity and effective signal transmission. Other recent studies have shown that glial cells, too, can respond to neuronal activity by changing their morphology and function, thereby participating in synaptic plasticity [13,14]. Disruptions in these neuron-glial interactions can lead to various neurological disorders, emphasizing the importance of understanding these relationships for therapeutic development in neurodegenerative diseases.

2.2 The Role of Glial Cells in Alzheimer's Disease

2.2.1 Glial Cell Response to Amyloid Plaques

The role of glial cells like astrocytes and microglia in Alzheimer's pathophysiology largely rests on their reaction to assembly into amyloid-beta plaques. These plaques are a signature feature of AD and are linked with neuroinflammation and neuronal degeneration. When Aβ accumulates, they initiate a reactive response from glial cells, which can be both protective or harmful. Astrocytes become activated and try to clear Aβ by means of phagocytosis. Microglia, brain-resident immune cells, also partake in the sweeping away of these plaques. However, excessive activation of the glial cells will lead to the chronic inflammatory state that exacerbates neuronal damage and further advances the progress of the pathology of AD [15]. Existing data have shown that glial cells can form a barrier to the Aβ plaques, but this can lock out the intervention of other glial cells from these plaques, thereby preventing effective clearing [16]. In addition, if the glial cells adopt pro-inflammatory phenotypes, the activated glial cells will release cytokines that then recruit other inflammatory mediators [17]. Then, it should be mentioned that the dual role played by the glial in response to Aβ is indispensable for targeted therapies that can either modulate activities of the glial in promoting plaque clearance or minimizing neuro-inflammation.

2.2.2 The Function of Glial Cells in Inflammatory Responses

Inflammation represents an important aspect of the pathogenesis of Alzheimer's disease. Glial cells play a key role in mediating these inflammatory responses. Microglia and astrocytes respond to many stimuli, including Aβ deposition and neuronal injury, by activating inflammatory pathways. This leads to further damage of neurons and contributes to neurodegeneration through the release of

pro-inflammatory cytokines [1]. While moderate activation of glial cells provides neuroprotective effects supporting neuronal survival and promoting repair processes, excessive or chronic activation can lead to an irreversible, destructive cycle of inflammation and neuronal death [5]. The state of activation of glial cells provides a fine balance between protective and harmful effects, thus understanding the mechanisms regulating glial cell polarization and activation is important to discerning potential therapeutic targets. Therapeutic strategies aiming to modulate glial responses, for example, using mesenchymal stem cell-derived extracellular vesicles to mitigate inflammation, are currently being explored [17]. These approaches could provide a means to harness the beneficial aspects of glial cell activation while reducing their detrimental effects in Alzheimer's disease.

2.2.3 Therapeutic Strategies Targeting Glial Cells

Shoeing the way glial cells play a role in the pathogenesis of Alzheimer's disease, targeting these different cells remains a valuable therapeutic strategy. Recent studies have therefore focused on modifying and activating glial cells to extend their protective abilities while lessening their inflammatory impact. One approach is the use of pharmaceutical therapy that can revert pro-inflammatory glial cells into the so-called anti-inflammatory bicycles, lessening the neuroinflammatory cascade while enhancing neuronal survival [7]. Other strategies also recently evaluated this area of research, including enhancing the metabolic support of the neurons by astrocytes, gem which would be supported because astrocytes are essential for neuronal health by regulating neurotransmitter levels and modulating energy metabolism [1]. Focus on other areas of research that develop therapies targeting the signaling pathways involving glial cell activation, for example, the purinergic signaling pathways shown to influence glial responses in neurodegenerative conditions [5]. Furthermore, the potential of gene therapy solution to modify the expression of specific proteins in glial cells is now being explored and may provide for very precise treatments based on the unique pathophysiological features of Alzheimer's disease [18]. Overall, advancing our understanding of glial cell biology in Alzheimer's disease will be crucial for developing effective therapies aimed at altering the course of this debilitating condition.

2.3 Progress in Glial Cell Research in Parkinson's Disease

2.3.1 The Impact of Glial Cells on Dopaminergic Neurons

It is known that glial cells, specifically astrocytes and microglia, are some of the critical players for the health and functionality of the dopaminergic neurons, which come under constant threat in Parkinson's disease (PD). Most recent enraged findings indicate that these glial cells do not only serve as a neuronal survival bulwark but are actually involved in the neuroinflammatory process, which becomes characteristic during the pathology of PD. For this, the abnormal accumulation of alpha-synuclein aggregates in neurons and glial cells is associated with neurodegenerative diseases including PD [4]. Glial cells have been mentioned to be associated with neurotransmitter levels and synaptic plasticity and their maintenance of dopaminergic signaling. They secrete neurotrophic factors, such as glial cell line-derived neurotrophic factor (GDNF), that promote the survival and differentiation of dopaminergic neurons [19]. Nonetheless, the impairment of glial cell functions could intensify the neurodegenerative process. For example, reactive astrogliosis and microglial activation contribute to chronic neuroinflammation, and consequently this leads to neuronal death and progression of PD [9]. THence, understanding the dual role of glial cells in supporting and harming dopaminergic neurons is vital in providing new insight in the field of therapy aimed at resisting PD.

2.3.2 The Relationship Between Intense Exercise and Glial Cell Function

Consistent physical training has affected the function and behavior of glial cells, which may involve potential clinical implications for neurodegenerative diseases such as Parkinson's disease. Exercise induces changes in physiology, which may confer neuroprotection or maintain neuroplasticity, opposing neurodegeneration processes seen in PD. For example, studies have shown that exercise can stimulate the release of neurotrophic factors from glial cells, possibly promoting the survival and functioning of dopaminergic neurons [1]. Moreover, exercise has been associated with increased expression of monocarboxylate transporters in astrocytes, facilitating lactate metabolism and providing energy substrates to neurons during high-demand situations [20]. The relationship, however, is complex; whereas moderate exercise seems to be beneficial, intense or excessive exercise may increase oxidative stress and inflammation and lead to glial cell dysfunction and possibly neurodegeneration [2]. Future research should fill this gap and find out what exercise program is good-a balance of glial cell protection and overdoing it.

2.3.3 Future Research Directions and Challenges

The research of glial cells in the setting of Parkinson's disease exudes both excitement and challenges. One promising avenue involves investigating glial cell metabolism in the context of neuroprotection. Recent evidence highlights glial metabolic dysregulation as a contributor to neuroinflammation and neurodegeneration, thus placing emphasis on studies on glial metabolism as a potential therapeutic measure [3]. Additionally, the role of glial cells in the clearance of alpha-synuclein aggregates warrants further investigation, as enhancing glial phagocytic activity could mitigate the toxic effects of these aggregates [21]. Nevertheless, there are some challenges yet, such as the need for a better understanding of the molecular mechanisms that guide glial cell activation and polarization in PD. Moreover, it is important to develop models in animals corresponding more closely to the human glial cells' behavior in PD for the translation of results into clinical application. Confronting these challenges will be important for exploiting the therapeutic capabilities of glial cells in dealing with Parkinson's disease and other related disorder treatments.

2.4 Mechanisms of Glial Cells in Multiple Sclerosis

2.4.1 Role of Glial Cells in the Demyelination Process

Various types of glial cells, including microglia, astrocytes,

and oligodendrocytes, are so implicated in the pathophysiology of multiple sclerosis (MS), with especial regards paid to their roles in demyelination. In the case of MS, the myelin sheath surrounding nerves is wrongly attacked by the immune system, thus causing substantial neurological limitation. Glial cells are not simply assistants but can play an active role in the inflammatory milieu that characterizes MS. Microglia are the resident immune cells of the CNS that are activated when demyelination occurs and participate in the neuroinflammatory process by releasing pro-inflammatory cytokines and chemokines that further recruit peripheral immune cells to the injury site [22]. In contrast, astrocytes may take on reactive states that, therefore, would either exacerbate damage or promote repair depending on their activation state and the surrounding microenvironment [23]. It rests a fair balance of neuroprotective versus neurotoxic effects of glial cells; normal glial responses facilitate remyelination and neuroregeneration, whereas deregulated activity becomes chronic neuroinflammatory and neurodegenerative [24]. Intercellular communication between glial cells and oligodendrocyte precursor cells (OPCs) is very important for remyelination because it controls survival of OPCs at least in part by influencing the differentiation into mature oligodendrocytes, which in turn can form new myelin sheaths [25]. A better understanding of the dual role played by glial cells in various neurological and neuroinflammatory diseases is paramount for their understanding in MS-specific targeted and efficient therapy.

2.4.2 Relationship Between Glial Cells and Immune Response

The relationship between glial cells and the immune response in multiple sclerosis is complex and multifaceted. In MS, the breakdown of the blood-brain barrier allows peripheral immune cells, such as T cells and macrophages, to infiltrate the central nervous system (CNS), where they interact with glial cells [22]. Upon immune challenges, activated microglia and astrocytes secrete several pro- or anti-inflammation cytokines and chemokines, inducing inflammation or stimulating repair processes. This dynamic is crucial for the course and pathology of MS wherein activated glial cells lead to the prolonged inflammatory response contributing to neuronal degeneration and demyelination [23]. Microglial polarization may yield either neuroprotective or neurotoxic effects depending on the cues from the surroundings [23]. Additionally, astrocytes can modulate immune responses by presenting antigens and secreting factors that influence T cell activation and differentiation [25]. Thus, it is becoming clearer that glial cells have more than just the role of support kirine about the health of the neurone, but that they are effectively part of an immune response that can shape the whole course of disease. Studies unraveling some of the above interactions might bring to light new therapeutic targets, aiming at modulating the functions of glial cells to restore immune balance in MS.

2.4.3 Prospective Applications in Therapy

Treating glial cells in MS has captured the interest of researchers, who understand they play critical roles not just in disease processes but also in disease repair. This being said, currently used treatment strategies usually modulate the immune response mechanism, with realization that there should indeed be an effort to directly affect glial-cell functions in order to promote remyelination and provide neuroprotection [24]. For instance, approaches promoting the protective functions of astrocytes and microglia or modulating their activation states may help with treating patients with MS. Novel approaches, including augmenting the metabolic support provided by astrocytes or promoting the phagocytic activity of microglia toward the clearance of myelin debris, are being researched [23]. Additionally, recent studies suggest that manipulating the signaling pathways involved in glial cell activation could shift their responses from pro-inflammatory to anti-inflammatory, potentially mitigating neurodegeneration [23]. Additionally, glial progenitor cell cell-based therapy has the promise in replenishing dead oligodendrocytes and promoting remyelination in future research [24]. With the increase in understanding of glial cell biology concerning MS, it is reasonable to foresee the development of new therapeutic strategies specifically targeting glial cells that may alter the course of the disease and improve patient outcomes.

2.5 Research on Glial Cells in Other Neurodegenerative Diseases

2.5.1 The Impact of Spinal Muscular Atrophy on Glial Cells

Spinal muscular atrophy (SMA) is a genetic disorder characterized by degeneration of motor neurons in the spinal cord. It primarily results in weakness of the muscle and the atrophy. The recent studies have expanded our view to consider the impact of glial cells on SMA development. Glial cells, including astrocytes and microglia, play important roles in neuronal health, viability, and synaptic actions. In SMA, these glial cells undergo profound changes, showing some altered activation state correlating with neuroinflammation and neuronal death. For example, astrocytes from both SMA models have become reactive by the process of secreting pro-inflammatory cytokines and chemokines, which can contribute to neuronal injury [1]. Furthermore, the activation of microglia in SMA seems to promote the elaboration of neurotoxic factors, further impairing motor neuron survival. The dysregulation of inflammation in glial cells in SMA not only targets motor neurons but shifts the homeostatic control of CNS overall. That means that targeting glial cell responses could become a new path to drugging attendant SMA progression for a better prognosis of affected individuals [4].

2.5.2 Pathological Studies of Glial Cells in Huntington's Disease

This degenerating disease is most commonly caused by the expansion of CAG repeats in the HTT gene, leading to the abnormal production of mutant huntingtin protein (mHTT). There is growing evidence that glial cells profoundly influence HD pathogenesis because they maintain neuronal function and promote the disease. It has been shown that glial cells in HD demonstrate the loss of certain normal functions along with the acquisition of painful phenotypes, which significantly affect) neuronal health. In particular, altered expression of neurotrophic factors and inflammatory mediators by astrocytes and microglia in HD may exacerbate neuron dysfunction and cell death [26]. Using induced

pluripotent stem cells (iPSCs) from HD patients, other studies demonstrated that expression of mHTT in several glial cell types is linked to cell-autonomous dysfunction, highlighting the importance of glial cells in the disease process [27]. The early malfunctioning of glial cells in HD, noted even prior to the onset of clinical motor and cognitive symptoms, emphasizes their possibility as a therapeutic target. Interventions that restore their normal functions or privileging decisions on restoring the glial cells could be viewed as promising strategies to delay the onset and progression of HD [28].

In conclusion, glial cells have emerged as key players in the pathophysiology of many neurodegenerative diseases. Their many aspects of function go well beyond their support of neurons; they initiate and progress diseases in a way that creates a delicate balance in neurodegeneration. This review emphasizes the demands for understanding the elaborate functions of glial cells, as these cultures inform our understanding of neuroinflammation, synaptic regulation, and neuroprotection.

From an expert point of view, it is essential that the diverse research views surrounding glial cells find their balance. Whereas historically they have been foisted into rather passive roles, the most recent studies have made it exceedingly clear about the dynamic capabilities of glial cells to affect neuronal health and disease. Although underappreciated, such observations call for re-evaluating the existing therapeutic paradigms tending to focus mostly on the neuronal pathways. Instead, future research must shed light on how glial cells act by merely detailing how they contribute to neurodegeneration. Understanding the different signaling pathways and molecular interactions involved may help establish new therapeutic strategies aimed at the modulation of glial cell functions.

It cannot be overstated how prominent glial cells have become as subjective therapeutic targets beyond the research that reveals various roles that glial cells have. Given the tremendous information still emerging from their discovery, developing interventions that may help enhance or inhibit glial cell activity stands to provide new strategies for treatment. Such interventions could instigate the development of targeted therapies that might not only ameliorate the symptoms of neurodegenerative diseases but also modify their relentless progression.

3. Summary

To sum it all up, the complexity of the interactions between glial cells and neurodegenerative disease can provide challenges for scientists and at the same time give them new opportunities. Through matured expression and understanding of glial cellular biology in relation to neurodegenerative contexts, we shall have more effective intervention strategies. It is with these promises that the future of neurodegenerative research lies, in being able to funnel this knowledge to the bedside and ultimately to improved outcomes for these complexly ill patients. In order to fully realize the therapeutic power of glial cells and pave the way for innovative treatments that can change the landscape for patients' living and lifestyle, significant research investments in the future will be necessary.

References

[1] Afridi R, Rahman MH, Suk K. Implications of glial metabolic dysregulation in the pathophysiology of neurodegenerative diseases. Neurobiol Dis. 174:105874.

[2] Méndez-Flores OG, Hernández-Kelly LC, Olivares-Bañuelos TN, López-Ramírez G, Ortega A. Brain energetics and glucose transport in metabolic diseases: role in neurodegeneration. Nutr Neurosci. 2024;27(10):1199-1210.

[3] Yang D, Wang X, Zhang L, et al. Lipid metabolism and storage in neuroglia: role in brain development and neurodegenerative diseases. Cell Biosci. 2022;12(1):106. Published 2022 Jul 12.

[4] Jeon YM, Kwon Y, Jo M, Lee S, Kim S, Kim HJ. The Role of Glial Mitochondria in α-Synuclein Toxicity. Front Cell Dev Biol. 8:548283. Published 2020.

[5] Pietrowski MJ, Gabr AA, Kozlov S, Blum D, Halle A, Carvalho K. Glial Purinergic Signaling in Neurodegeneration. Front Neurol. 12:654850. Published 2021.

[6] Ki SM, Jeong HS, Lee JE. Primary Cilia in Glial Cells: An Oasis in the Journey to Overcoming Neurodegenerative Diseases. Front Neurosci. 15:736888. Published 2021.

[7] Kalsariya RA, Kavila D, Shorter S, et al. Molecular biomarkers of glial activation and injury in epilepsy. Drug Discov Today. 2025;30(2):104289. Published online Jan 10, 2025.

[8] Huang J, Li C, Shang H. Astrocytes in Neurodegeneration: Inspiration From Genetics. Front Neurosci. 16:882316. Published 2022.

[9] Cragnolini AB, Lampitella G, Virtuoso A, et al. Regional brain susceptibility to neurodegeneration: what is the role of glial cells? Neural Regen Res. 2020;15(5):838-842.

[10] Bernstein HG, Nussbaumer M, Vasilevska V, et al. Glial cell deficits are a key feature of schizophrenia: implications for neuronal circuit maintenance and histological differentiation from classical neurodegeneration. Mol Psychiatry. Published online Dec 5, 2024.

[11] Lee E, Chung WS. Glial Control of Synapse Number in Healthy and Diseased Brain. Front Cell Neurosci. 13:42. Published 2019.

[12] Blank N, Weiner M, Patel S, Köhler S, Thaiss CA. Mind the GAPS: Glia associated with psychological stress. J Neuroendocrinol. e13451. Published online Oct 9, 2024.

[13] Sanchini G, Vaes N, Boesmans W. Mini-review: Enteric glial cell heterogeneity: Is it all about the niche? Neurosci Lett. 812:137396.

[14] Afridi R, Kim JH, Rahman MH, Suk K. Metabolic Regulation of Glial Phenotypes: Implications in Neuron-Glia Interactions and Neurological Disorders. Front Cell Neurosci. 14:20. Published 2020.

[15] Al-Ghraiybah NF, Wang J, Alkhalifa AE, et al. Glial Cell-Mediated Neuroinflammation in Alzheimer's Disease. Int J Mol Sci. 2022;23(18). Published 2022 Sep 12.

[16] Huang Y, Wang M, Ni H, et al. Regulation of cell distancing in peri-plaque glial nets by Plexin-B1 affects

glial activation and amyloid compaction in Alzheimer's disease. Nat Neurosci. 2024;27(8):1489-1504.
[17] Ye Y, Gao M, Shi W, et al. The immunomodulatory effects of mesenchymal stem cell-derived extracellular vesicles in Alzheimer's disease. Front Immunol. 14:1325530. Published 2023.
[18] Jia H, Xie T. Tracers progress for positron emission tomography imaging of glial-related disease. J Biomed Res. 2022;36(5):321-335.
[19] Kakoty V, Sarathlal KC, Kaur P, et al. Unraveling the role of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease. Neurol Sci. 2024;45(4):1409-1418.
[20] Gao C, Yang B, Li Y, Pei W. A monocarboxylate transporter-dependent mechanism confers resistance to exercise-induced fatigue in a high-altitude hypoxic environment. Sci Rep. 2023;13(1):2949. Published 2023 Feb 20.
[21] Kim JH, Huh E, Eo H, et al. Tribuli Fructus alleviates 1-methyl-4-phenyl 1, 2, 3, 6-tetrahydropyridine (MPTP)-induced Parkinson's disease by suppressing neuroinflammation via JNK signaling. Metab Brain Dis. 2024;40(1):69. Published 2024 Dec 19.
[22] Chu T, Shields LBE, Zeng W, et al. Dynamic glial response and crosstalk in demyelination-remyelination and neurodegeneration processes. Neural Regen Res. 2021;16(7):1359-1368.
[23] Liu Y, Wu L, Peng W, Mao X. Glial polarization in neurological diseases: Molecular mechanisms and therapeutic opportunities. Ageing Res Rev. 104:102638. Published online Dec 12, 2024.
[24] Wilbanks B, Maher LJ 3rd, Rodriguez M. Glial cells as therapeutic targets in progressive multiple sclerosis. Expert Rev Neurother. 2019;19(6):481-494.
[25] Sun Y, Yu H, Guan Y. Glia Connect Inflammation and Neurodegeneration in Multiple Sclerosis. Neurosci Bull. 2023;39(3):466-478.
[26] Wilton DK, Stevens B. The contribution of glial cells to Huntington's disease pathogenesis. Neurobiol Dis. 143:104963.
[27] Albert K, Niskanen J, Kälvälä S, Lehtonen Š. Utilising Induced Pluripotent Stem Cells in Neurodegenerative Disease Research: Focus on Glia. Int J Mol Sci. 2021;22(9). Published 2021 Apr 21.
[28] Yang J, Li H, Zhao Y. Dessert or Poison? The Roles of Glycosylation in Alzheimer's, Parkinson's, Huntington's Disease, and Amyotrophic Lateral Sclerosis. Chembiochem. 2023;24(16):e202300017.